IsoRay

IsoRay Equity

Delisted

The The Equity of IsoRay (ISR) as of Nov 4, 2026 is 61.28 M USD. In the previous year, The Equity was 67.41 M USD — a change of -9.09% (lower).

Equity

61.28 MUSD

YoY

-9.09%

Last updated:

In 2022, IsoRay's equity was 61.28 M USD, a -9.09% increase from the 67.41 M USD equity in the previous year.

The IsoRay Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
20.78 M USD
Jan 1, 2016
16.40 M USD
Jan 1, 2017
10.60 M USD
Jan 1, 2018
5.03 M USD
Jan 1, 2019
7.68 M USD
Jan 1, 2020
5.72 M USD
Jan 1, 2021
67.41 M USD
Jan 1, 2022
61.28 M USD
The IsoRay Equity history
YEAREquityYoY
61.28 MUSD-9.09%
67.41 MUSD+1,077.81%
5.72 MUSD-25.48%
7.68 MUSD+52.68%
5.03 MUSD-52.56%
10.60 MUSD-35.36%
16.40 MUSD-21.08%
20.78 MUSD-13.25%
23.96 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

Equity Details

Analyzing IsoRay's Equity

IsoRay's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding IsoRay's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating IsoRay's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

IsoRay's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in IsoRay’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about IsoRay stock

The Equity of IsoRay is 61.28 M USD in 2022.

The Equity of IsoRay changed from 67.41 M USD to 61.28 M USD, representing a -9.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity IsoRay since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's IsoRay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IsoRay

All Key Metrics — IsoRay